Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01054443 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP)
A Phase 2 study, sponsored by Shionogi.
- Terminated
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT01054443 is a Phase 2 study that was terminated before completion, run by Shionogi. The registered enrollment target is 20 participants.
The verdict
NCT01054443, a Phase 2 study, was terminated before completion, sponsored by Shionogi.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The primary objective of this study was to assess the efficacy of 3 dose levels of lusutrombopag (0.5 mg, 0.75 mg, and 1.0 mg) and placebo on platelet count.
Interventions
- DRUG Placebo
- DRUG Lusutrombopag
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2010-03-18 |
| Est. Completion | 2010-11-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01054443
The ClinicalTrials.gov registry entry for NCT01054443 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shionogi, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01054443 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01054443 about?
NCT01054443 is a clinical study titled "A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP)". The primary objective of this study was to assess the efficacy of 3 dose levels of lusutrombopag (0.5 mg, 0.75 mg, and 1.0 mg) and placebo on platelet count.
What is the current status of trial NCT01054443?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2010-03-18. Estimated completion is 2010-11-24.
What interventions are being tested in trial NCT01054443?
The interventions under investigation include: Placebo (DRUG), Lusutrombopag (DRUG).
Who is sponsoring clinical trial NCT01054443?
This trial is sponsored by Shionogi, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.